Residual Pulmonary Hypertension
Conditions
Brief summary
To assess the effectiveness of the synthetic analogue of prostacyclin in postembolic residual pulmonary hypertension.
Interventions
DRUGVentavis
DRUGWarfarin
Sponsors
Meshalkin Research Institute of Pathology of Circulation
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Patients with pulmonary embolism after undergone surgical treatment (intravascular thrombolysis, catheter thrombus fragmentation) * Patients with preserved thromboembolism in the pulmonary circulation system and mean pressure in the pulmonary artery of more than 25 mm Hg
Exclusion criteria
* Patient did not sign the informed consent. * Mean pulmonary artery pressure after surgical treatment less than 25 mm Hg * Age above 75 years. * Patients with an increased risk of bleeding - including gastric ulcer and 12 duodenal ulcer in acute, hemorrhagic stroke. * Severe coronary artery disease (unstable angina, myocardial infarction within the last 6 months). * Acute heart failure or CHF IV in NYHA. * Severe arrhythmias. * Pregnancy, lactation. * The presence of severe diseases of other organ systems that may result in death during the first year after surgery.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pulmonary hypertension | 6 months | The average pressure in the pulmonary artery trunk (according to direct tensiometry before Ventavis therapy, after the therapy according to transthoracic echocardiography and six months after discharge (transthoracic echocardiography). |
Secondary
| Measure | Time frame |
|---|---|
| Number of deaths | 6 months |
| Number of recurrent pulmonary embolisms | 6 months |
| Number of venous thromboembolisms | 6 months |
Countries
Russia
Contacts
Primary ContactYulia Klevanets, MD
Outcome results
None listed